MASCOT : Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV
NCT00263055 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL
Last updated 2009-09-15
Summary
Safety \& tolerability of FOLFOX4 regimen in the adjuvant treatment of colon cancer in Asian patients
Conditions
- Colonic Neoplasms
Interventions
- DRUG
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Claude Valterio, MD · Sanofi
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-08-31
- Primary Completion
- 2005-06-30
Countries
- China
- Hong Kong
- South Korea
- Taiwan
- Thailand
Study Locations
More Related Trials
-
Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC
NCT02024412 ·Status: UNKNOWN ·Phase: PHASE3
-
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
NCT04169347 ·Status: UNKNOWN ·Phase: PHASE2
-
Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer
NCT01972503 ·Status: UNKNOWN ·Phase: PHASE4
-
Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer
NCT00205322 ·Status: COMPLETED ·Phase: PHASE2
-
Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM
NCT03493048 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer
NCT05335460 ·Status: UNKNOWN ·Phase: PHASE2
-
Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer
NCT00689624 ·Status: COMPLETED ·Phase: PHASE2
-
Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)
NCT00125034 ·Status: COMPLETED ·Phase: PHASE2
-
Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive
NCT07337551 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer
NCT06335147 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer
NCT06890624 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients
NCT01228734 ·Status: COMPLETED ·Phase: PHASE3
-
OPTIMOX1 in Chinese mCRC Patients
NCT01023633 ·Status: UNKNOWN ·Phase: PHASE4
-
Feasibility Study of mFOLFOX6 in Patients With Advanced Colorectal Cancer
NCT00209703 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Fruquintinib in Patients With Metastatic Colorectal Cancer
NCT02196688 ·Status: COMPLETED ·Phase: PHASE2
-
Colorectal Cancer RECHALLENGE
NCT00988897 ·Status: WITHDRAWN ·Phase: PHASE2
-
FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer
NCT05797883 ·Status: UNKNOWN ·Phase: PHASE2
-
Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE)
NCT03043950 ·Status: COMPLETED
-
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer
NCT06115174 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM
NCT03493061 ·Status: COMPLETED ·Phase: PHASE2
-
Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer
NCT05004441 ·Status: UNKNOWN ·Phase: PHASE2
-
Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer
NCT00721916 ·Status: COMPLETED ·Phase: PHASE2
-
Retrospective Evaluation of 5-FU Exposure Optimization in CRC Patients
NCT02055560 ·Status: COMPLETED
-
Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.
NCT00439517 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)
NCT06959693 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3